



Senate

General Assembly

File No. 575

February Session, 2018

Substitute Senate Bill No. 379

Senate, April 18, 2018

The Committee on Appropriations reported through SEN. OSTEN of the 19th Dist. and SEN. FORMICA of the 20th Dist., Chairpersons of the Committee on the part of the Senate, that the substitute bill ought to pass.

***AN ACT LIMITING CHANGES TO HEALTH INSURERS'
PRESCRIPTION DRUG FORMULARIES.***

Be it enacted by the Senate and House of Representatives in General Assembly convened:

1 Section 1. Section 38a-492f of the general statutes is repealed and the
2 following is substituted in lieu thereof (*Effective January 1, 2019*):

3 Each individual health insurance policy providing coverage of the
4 type specified in subdivisions (1), (2), (4), (11), [and] (12) and (16) of
5 section 38a-469 delivered, issued for delivery, renewed, amended or
6 continued in this state that provides coverage for outpatient
7 prescription drugs and imposes a coinsurance, copayment, deductible
8 or other out-of-pocket expense that is more than forty dollars for any
9 covered prescription drug shall not [deny coverage for an insured for
10 any drug that the insurer removes from its list of covered drugs, or
11 otherwise ceases to provide coverage for, if (1) the insured was using
12 the drug for the treatment of a chronic illness prior to the removal or
13 cessation of coverage, (2) the insured was covered under the policy for

14 the drug prior to the removal or cessation of coverage, and (3) the
15 insured's attending health care provider states in writing, after the
16 removal or cessation of coverage, that the drug is medically necessary
17 and lists the reasons why the drug is more medically beneficial than
18 the drugs on the list of covered drugs. Such benefits shall be subject to
19 the same terms and conditions applicable to all other benefits under
20 such policies] remove any covered prescription drug from its list of
21 covered drugs or reclassify or place the drug in a higher cost-sharing
22 tier for the duration of the policy term, except a covered prescription
23 drug may be removed from the list if (1) (A) the drug is not medically
24 necessary, (B) the health carrier that delivered, issued, renewed,
25 amended or continued the policy provides the insured and the
26 insured's prescribing health care provider with at least sixty days'
27 advance written notice of its intended action, and (C) the insured's
28 prescribing health care provider agrees that the drug is not medically
29 necessary, or (2) the drug is identified as no longer safe and effective
30 by the federal Food and Drug Administration or by peer-reviewed
31 medical literature generally recognized by the relevant medical
32 community. Nothing in this section shall be construed to prohibit the
33 addition of prescription drugs to such policy's list of covered drugs
34 during a policy term, provided the addition does not affect such
35 covered prescription drugs, or the classification or cost-sharing tier of
36 such drugs, already on the list during the policy term.

37 Sec. 2. Section 38a-518f of the general statutes is repealed and the
38 following is substituted in lieu thereof (*Effective January 1, 2019*):

39 Each group health insurance policy providing coverage of the type
40 specified in subdivisions (1), (2), (4), (11), [and] (12) and (16) of section
41 38a-469 delivered, issued for delivery, renewed, amended or continued
42 in this state that provides coverage for outpatient prescription drugs
43 and imposes a coinsurance, copayment, deductible or other out-of-
44 pocket expense that is more than forty dollars for any covered
45 prescription drug shall not [deny coverage for an insured for any drug
46 that the insurer removes from its list of covered drugs, or otherwise
47 ceases to provide coverage for, if (1) the insured was using the drug for

48 the treatment of a chronic illness prior to the removal or cessation of
 49 coverage, (2) the insured was covered under the policy for the drug
 50 prior to the removal or cessation of coverage, and (3) the insured's
 51 attending health care provider states in writing, after the removal or
 52 cessation of coverage, that the drug is medically necessary and lists the
 53 reasons why the drug is more medically beneficial than the drugs on
 54 the list of covered drugs. Such benefits shall be subject to the same
 55 terms and conditions applicable to all other benefits under such
 56 policies] remove any covered prescription drug from its list of covered
 57 drugs or reclassify or place the drug in a higher cost-sharing tier for
 58 the duration of the policy term, except a covered prescription drug
 59 may be removed from the list if (1) (A) the drug is not medically
 60 necessary, (B) the health carrier that delivered, issued, renewed,
 61 amended or continued the policy provides the insured and the
 62 insured's prescribing health care provider with at least sixty days'
 63 advance written notice of its intended action, and (C) the insured's
 64 prescribing health care provider agrees that the drug is not medically
 65 necessary, or (2) the drug is identified as no longer safe and effective
 66 by the federal Food and Drug Administration or by peer-reviewed
 67 medical literature generally recognized by the relevant medical
 68 community. Nothing in this section shall be construed to prohibit the
 69 addition of prescription drugs to such policy's list of covered drugs
 70 during a policy term, provided the addition does not affect such
 71 covered prescription drugs, or the classification or cost-sharing tier of
 72 such drugs, already on the list during the policy term.

This act shall take effect as follows and shall amend the following sections:

Section 1	January 1, 2019	38a-492f
Sec. 2	January 1, 2019	38a-518f

APP

Joint Favorable Subst.

The following Fiscal Impact Statement and Bill Analysis are prepared for the benefit of the members of the General Assembly, solely for purposes of information, summarization and explanation and do not represent the intent of the General Assembly or either chamber thereof for any purpose. In general, fiscal impacts are based upon a variety of informational sources, including the analyst's professional knowledge. Whenever applicable, agency data is consulted as part of the analysis, however final products do not necessarily reflect an assessment from any specific department.

OFA Fiscal Note

State Impact: None

Municipal Impact:

Municipalities	Effect	FY 19 \$	FY 20 \$
Various Municipalities	STATE MANDATE - Cost	See Below	See Below

Explanation

The bill does not result in a fiscal impact to the state employee and retiree health plan as the state plan does not meet the cost sharing provisions of the bill.

The bill will increase costs to certain fully insured municipal plans to comply with the provisions of the bill. The coverage requirements will result in increased premium costs when municipalities enter into new health insurance contracts after January 1, 2019. In addition, many municipal health plans are recognized as “grandfathered” health plans under the ACA.¹ It is unclear what effect the adoption of certain health mandates will have on the grandfathered status of certain municipal plans under ACA. Pursuant to federal law, self-insured health plans are exempt from state health mandates.

The Out Years

The annualized ongoing fiscal impact identified above will continue into the future and be reflected in plan premiums.

¹ Grandfathered plans include most group insurance plans and some individual health plans created or purchased on or before March 23, 2010. Generally, grandfathered plans are not required to provide coverage for EHBs.

OFA Bill Analysis**SB 379*****AN ACT LIMITING CHANGES TO HEALTH INSURERS' PRESCRIPTION DRUG FORMULARIES.*****SUMMARY:**

This bill generally prohibits insurers and HMOs from removing from a formulary (i.e., a list of covered prescription drugs) or reclassifying any covered drug during a health insurance policy's term.

Specifically, under the bill, insurers and HMOs that cover outpatient prescription drugs cannot remove a covered drug from a formulary or reclassify a drug into a higher cost-sharing tier during a policy's term. However, they can remove a drug from a formulary if (1) it is determined not to be medically necessary in concurrence with the prescribing provider and the carrier provides at least 60 days' notice to the insured and prescribing provider or (2) it is deemed no longer safe and effective by the U.S. Food and Drug Administration or peer-reviewed medical literature generally recognized by the relevant medical community. Additionally, the bill allows them to add drugs to the formulary during a policy term, as long as doing so does not affect the coverage or cost-sharing for drugs already on the formulary.

The bill applies to individual and group health insurance policies delivered, issued, renewed, amended, or continued in Connecticut that cover (1) basic hospital expenses; (2) basic medical-surgical expenses; (3) major medical expenses; (4) hospital or medical services, including those provided under an HMO plan; or (5) ancillary services, such as dental, vision, or prescription drugs, (6) and imposes cost-sharing for any covered prescription that is more than forty dollars. Because of the federal Employee Retirement Income Security Act (ERISA), state insurance benefit laws do not apply to self-insured benefit plans.

Current law allows insurers and HMOs to remove drugs from a formulary during a policy's term. But it prohibits them from denying coverage for any drug removed from the formulary if (1) the insured was using the drug to treat a chronic illness and had been covered for it before the removal and (2) his or her attending physician states in writing, after the removal, that the drug is medically necessary and why it is more beneficial than other drugs on the formulary.

EFFECTIVE DATE: *Effective January 1, 2019*

COMMITTEE ACTION

Appropriations Committee

Joint Favorable Substitute

Yea 42 Nay 7 (04/05/2018)